Company: STAA
Filing Date: 2025-10-21
Form Type: PX14A6G
Source: 0001193125-25-244217
Chunk: 2

Company: STAAR SURGICAL CO
Filing Date: 2025-10-21
Form: PX14A6G
Chunk 2
---
 Company itself has emphasized in past earnings materials.

As to the Company’s recent, corrective disclosures, we appreciate that these are a step in the right direction of informing shareholders about the
proposed merger. STAAR’s corrective press release of October 16 appropriately confirmed the existence of outreach by a third party – “Party C” – to CEO Stephen Farrell and Chair Elizabeth Yeu, which the Company did
not previously disclose to shareholders.

But while this update from the Company is welcomed, it is also cryptic and invites more questions, such as
whether initial interests from other parties have remained undisclosed or were similarly not followed up on by the Company. The important point for us as STAAR shareholders is the actions STAAR took – or failed to take – to explore this
outreach as part of an effort to seek value for shareholders.When STAAR’s CEO began reengaging with Alcon in June 2025, the correspondence from Party C was in recent memory. Yet apparently no effort was made by the Company to follow up
or to learn anything more about the nature of Party C’s interest. So, we appreciate that shareholders now know, as STAAR says in its corrective press release, that Party C’s email “was not followed up on by Party C.” But more
important to us is that Party C’s email was not followed up on by STAAR.

2. The Company Should Hold the Special Meeting on October 23 as Planned and Resist Pressure from Alcon to Delay

The Company should hold the vote on the Proposed Merger as scheduled on October 23, 2025, without
delay or the pretense of shareholders needing more time to consider the information at hand. The Board should also reject any pressure from Alcon to that end as part of an effort by Alcon to support its own predatory acquisition of the Company and
its ongoing pattern of serial acquisitions in the ophthalmology space.

Shareholders already have the information they need, and the three proxy advisors
have given their recommendations. We are aware of what the Company has done and said regarding the transaction. Every week the Company delays the vote, its market recovery and broader trajectory remain in limbo and the Board and management are
delayed in course correcting.

We also urge the Company not to amend the merger agreement in an effort to suddenly and belatedly create more time for the
Board to “shop” the Company between now and a delayed special meeting to approve the proposed merger with Alcon. We believe that the Company cannot be effectively and fairly